Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC ...

Moderna has launched Phase 3 human trials of its mRNA-based H5N1 avian influenza vaccine, aiming to preempt a potential pandemic threat. The vaccine uses the same platform as Moderna’s COVID-19 shot ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...

April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal ...

Moderna has begun a Phase 3 trial of its mRNA-1018 vaccine against the H5N1 bird flu, with the first volunteers receiving doses in the UK and US. The study will test safety and immune response in ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Moderna Inc. said Monday it was asking U.S.

Moderna (MRNA) Tuesday said that the U.S. Food and Drug Administration will not initiate a review of the biologics license application for its investigational influenza vaccine, mRNA-1010, and has ...

Feb 10 (Reuters) - The U.S. Food and Drug Administration will not review Moderna's (MRNA.O), opens new tab approval application for its influenza vaccine, the company said on Tuesday, sending its ...

Bird flu vaccine trial begins to fight ‘real possibility’ of virus threat for humans - The vaccine will utilise mRNA ...

Now, it’s worth noting Stock Advisor’s total average return is 986 % — a market-crushing outperformance compared to 199% for ...